Continuing Medical Education Programs and Self Assessment Modules
ASTRO continues to strive to meet the educational needs of its members. In addition to providing online courses approved for AMA PRA Category 1 Credit, many of our online offerings are approved by the American Board of Radiology in meeting the criteria for self assessment credit toward the purpose of fulfilling requirements in the ABR Maintenance of Certification Program. These peer-reviewed modules are based upon previously distributed, peer-reviewed materials in a variety of subspecialty content areas.
Target Audience This program is designed to meet the interest of radiation oncologists, radiation oncology residents, radiation biologists, radiation physicists, dosimetrists, oncologists working in related specialties, radiation therapists, radiation oncology nurses, radiation oncology administrators and all other health professionals involved in the field of radiation oncology.
Continuing Medical Education The American Society for Radiation Oncology is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation ASTRO designates this educational activity for 1.5 AMA PRA Category 1 Credit™ and 1 SAM credit. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Qualified by the American Board of Radiology in meeting the criteria for self assessment toward the purpose of fulfilling requirements in the ABR Maintenance of Certification Program.
Approximate Length: 1 hour 30 minutes Format: Synchronized audio and PowerPoint Hardware/ Software Requirements: Windows 2000 or newer, Internet Explorer 5.0 or higher, free Flash plug-in, Internet connection (broadband recommended), speakers or sound card. Accessibility: Any time/any day for one year from registration date.
The recent Flash Player version 9 security update and the Flash Player 10 software that caused problems with our courses has been remedied. If you continue to have issues, please e-mail us.
Available for Credit: December 20, 2007, through December 19, 2010 Cost: $50 member (discounted for meeting attendees) - Register
Objectives
Discuss the incidence, prevalence, mortality, morbidity and clinical impact of the major malignant and benign adult primary CNS tumors.
Recognize the substantial heterogeneity that exists within these tumor types and understand the prognostic and predictive variables allowing for appropriate selection of therapeutic choices, tailored for a specific patient.
Be familiar with the major levels of evidence for therapeutic decision-making.
Appreciate the role of various therapies, especially surgery, radiotherapy and chemotherapy in managing these tumors.
Gain a preliminary understanding of the molecular biology of these diseases, especially in terms of how it might impact therapeutic decision-making.
Available for Credit: May 5, 2008, through May 4, 2011 Cost: $50 member (discounted for meeting attendees) - Register
Objectives:
Epidemiology of breast cancer in the U.S.
Risk factors for breast cancer development.
Screening and prevention.
Diagnosis and staging.
DCIS.
Early-stage breast cancer.
Breast-conserved intermediate disease.
To understand the prognostic factors for the local-regional recurrence in intermediate-stage and locally advanced breast cancer.
To understand the treatment techniques for post-mastectomy radiation in locally advanced breast cancer, inflammatory breast cancer, and locally recurrent breast cancer.
To understand important factors affecting radiation treatment in patients with post-mastectomy breast reconstruction.
Available for Credit: December 13, 2007, through December 12, 2010 Cost: $50 member (discounted for meeting attendees) - Register
Objectives
Realize technical aspects related to the delivery of radiation in patients with early-stage breast cancer, including use of a boost; IMRT techniques, management of the regional lymphatics and alternate fractionation schemes.
Discuss the selection factors, techniques, potential role and future directions of accelerated partial breast irradiation in the management of women with early-stage breast cancer.
Disclosures: *SenoRx Consultant/Advisory Board;**Stated no disclosure.
Available for credit: June 15, 2009, through June 14, 2012 Cost: $50 member (discounted for meeting attendees) - Register
Objectives:
Lower GI
Malignancies
Describe the most important prognostic factors for rectal cancer.
Describe the proven advantages of preoperative compared to postoperative chemoradiation in rectal cancer.
Understand the appropriate post-treatment follow-up for anal cancer patients and the indications for biopsy of suspected persistent or recurrent disease.
Describe the potential benefit of IMRT for anal cancer.
Upper GI
Malignancies
Describe the role of chemoradiation for esophageal, GE junction and gastric cancers.
Compare and contrast role of surgery for esophageal, GE junction and gastric cancers.
Understand limitations of the phase III evidence evaluating the use of chemoradiation in resected pancreatic cancer.
Describe a rational approach to the treatment of locally advanced pancreatic cancer based on the pattern of spread and limitations of existing therapies.
Disclosures: Honoraria and
Research Funding – Roche
49th ASTRO Annual Meeting 2007
Cancer of the Esophagus, GE Junction and Stomach
Available for Credit: March 24, 2008 through March 24, 2011 Cost: $50 member (discounted for meeting attendees) - Register
Objectives:
Review current epidemiological changes in esophageal cancer.
Discuss current treatment strategies of esophageal, GE junctional and gastric cancer; neoadjuvant treatment and surgery; surgery and adjuvant therapy; the role of surgery and definitive chemoradiation therapy.
Discuss future treatment strategies in these diseases.
Available for Credit: January 1, 2008, through December 31, 2010 Cost: $50 member (discounted for meeting attendees) - Register
Objectives
Describe how to use pretreatment clinical parameters and patient factors to optimize the radiotherapeutic treatment option(s) for patients with clinically localized disease.
Examine cancer control and potential complications and their actuarial occurrence following radiation therapy for patients with clinically localized disease.
Discuss how to sequence and administer androgen suppression therapy in conjunction with radiation therapy in men with high risk localized and locally advanced prostate cancer.
Discuss the potential complications and their actuarial occurrence of combined androgen suppression and radiation therapy.
Discuss the complications and their actuarial incidence of salvage therapies for a rising PSA after primary therapy for localized and locally advanced prostate cancer.
Identify when to use salvage hormonal therapy following primary treatment failure for localized or locally advanced prostate cancer and when further local therapy may be appropriate.
49th ASTRO Annual Meeting 2007
Brachytherapy for Gyn Neoplasms: (HDR and LDR)
Presenters: Patricia J. Eifel, M.D.*, M.D. Anderson Cancer Center; Akila N. Viswanathan, M.D., M.P.H.**, Brigham and Women's Hospital/Dana-Farber Cancer Institute
Available for Credit: December 17, 2007, through December 16, 2010 Cost: $50 member (discounted for meeting attendees) - Register
Objectives
Discuss the role of brachytherapy for treatment of gynecological malignancies.
Examine high-dose-rate and low-dose-rate systems and interstitial and intracavity techniques and treatment outcomes. Particular emphasis will be given to the use of this treatment modality for carcinoma of the cervix.
50th ASTRO Annual Meeting 2008
Nuclear Preparedness Training Course - Part 2 - Treatment of Exposed Patients
Presenters: Jacqueline P. Williams, Ph.D., University of Rochester Medical Center
and
William E. Dickerson, M.D., National Naval Medical Center
Available for Credit: December 29, 2008, through December 22, 2011 Cost: $50 member - Register
Objectives
Explain the diagnosis and treatment of the Acute Radiation Syndrome (ARS).
Discuss the diagnosis and treatment following external and internal contamination.
Explain the diagnosis and treatment of the Acute Radiation Syndrome (ARS)
Discuss the diagnosis and treatment following external and internal contamination.
ASTRO Spring Refresher 2008
Photon and Electron Dosimetry and Brachytherapy
Presenters: Indrid J. Chetty, Ph.D.*
Henry Ford Health System, Radiation Physics Division
Available for Credit: June 15, 2008, through June 14, 2011 Cost: $50 member (discounted for meeting attendees) - Register
Objectives
Review of particle interactions for photons and electrons: kerma and dose, charged particle equilibrium.
Discuss particle interactions in the accelerator treatment head; depth dose and profile characteristics for photon beams.
Discuss external beam dosimetry fundamentals for photon and electron beams: PDD, TAR, BSF, TPR, inverse square law, output factors; dose characteristics for electron beams.
Available for Credit: November 1, 2008 through October 31, 2011 Cost: $50 member (discounted for meeting attendees) - Register
Objectives:
Discuss the physiological differences between the processes of apoptosis, necrosis and senescence.
Justify the role that these important biological functions play in both normal and reactive physiology, with a particular emphasis on their role in the response to radiation injury.
Discuss the possibilities of using the molecular mechanisms involved as targets for therapy.
49th ASTRO Annual Meeting 2007
Cancer Genetics and Genetic Testing for the Practicing Radiation Oncologist
Presenter:James S. Welsh, M.D., M.S.*, University of Wisconsin Cancer Center and University of Wisconsin
Available for Credit: December 21, 2007 through December 20, 2010 Cost: $50 member (discounted for meeting attendees) - Register
Objectives
Become familiar with the inheritance patterns, genetic mechanisms, and basic biology of cancer predisposition syndromes that are routinely encountered by practicing radiation oncologists.
Learn the general management recommendations for patients harboring deleterious mutations as well as potential radiotherapeutic management differences that might apply to such patients.
Become familiar with the practical, ethical and legal issues surrounding cancer genetic testing and gain the fundamental knowledge necessary to carry our such testing on their own or create a formal genetics testing program at their institution.
Presenter: Elizabeth H. Baldini, M.D., M.P.H., Brigham and Women's Hospital/ Dana-Farber Cancer Institute; John Abraham, M.D.,
Brigham and Women's Hospital/ Dana-Farber Cancer Institute
Available for Credit: December 1, 2008 through November 30, 2011 Cost: $50 member (discounted for meeting attendees) - Register
Objectives
Natural History of Soft Tissue Sarcoma.
Indications for Radiation Therapy in Soft Tissue Sarcoma.
Radiation Therapy Technique for Soft Tissue Sarcoma.
Presenter: Jeffrey A. Bogart, M.D., State University of New York Upstate Medical University, and Frank C. Detterbeck, M.D., Yale University School of Medicine
Available for Credit: December 8, 2008 through December 7, 2011 Cost: $50 member - Register
Objectives
Explain the expected outcomes with standard surgery for early stage NSCLC.
Describe surgical and non-surgical options for patients with compromised lung function and early stage NSCLC.
Compare the risks and benefits of alternative therapies for early stage NSCLC.
